CRSP
CRISPR Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CRSP Profile
Crispr Therapeutics Ag
A biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases
Biological Technology
10/31/2013
10/19/2016
NASDAQ Stock Exchange
393
12-31
Common stock
Baarerstrasse 14, 6300 Zug, Switzerland
--
CRISPR Therapeutics AG was incorporated as a Swiss joint stock company under Inception Genomics AG on October 31, 2013. They are a leading genetic research company focusing on the development of CRISPR/Cas 9 therapies. CRISPR/Cas 9 stands for Cluster, Periodically Interspaced Short Palindrome Repeat (CRISPR) Related Protein 9, a revolutionary technology in the process of altering the arrangement of genes and the specific sequence of genomic DNA. They are applying this technique to treat a wide range of rare or common diseases by disrupting, correcting or modulating disease-related genes. Their most advanced project is for β-thalassemia and sickle cell disease, the treatment of which requires two hemoglobins for high medical needs.
